Liver X receptor (LXR) signaling in macrophage inflammation and cardiometabolic disease

Clicks: 9
ID: 331500
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #127 of 140 articles by views in cardiovascular research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 140 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Cardiometabolic diseases profoundly remodel tissue immune landscapes, characterized by the accumulation of diverse macrophage subtypes. Among these, lipid-associated macrophages (LAMs) have emerged as an important subset that is frequently observed in cardiometabolically affected tissues. LAMs are defined by a transcriptional profile linked to lipid metabolism and processing. In parallel, the nuclear receptor liver X receptor (LXR), is a key transcription factor that regulates cholesterol efflux, fatty-acid synthesis, as well as inflammation pathways. Through these pathways, LXR agonism has been shown to limit atherosclerosis progression but also to promote hepatic steatosis. Beyond lipid metabolism, LXRs exert important immunoregulatory functions. In murine macrophages, LXR activation consistently dampens inflammatory responses. In contrast, human macrophages show more heterogeneous responses, with several studies indicating that LXRs can also promote pro-inflammatory gene programs. These species-specific differences highlight a critical gap that currently limits the translation of preclinical findings. In this review, we integrate recent insights of LXRs in LAMs and cardiometabolic disease, emphasizing species-specific differences in macrophage LXR signaling between mice and humans. We discuss the contribution of LXR isoforms and emerging mechanisms by which LXRs influence inflammatory responses, and consider their implications for therapeutic targeting.
Reference Key
openalex_W7220356207 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lobke F. Zijlstra, Menno P.J. de Winther, Sander Kooijman, Antonio Castrillo, Annette E. Neele
Journal cardiovascular research
Year 2026
DOI
10.1093/cvr/cvag214
URL
https://doi.org/10.1093/cvr/cvag214
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.